S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
Log in
NASDAQ:ENDP

Endo International Competitors

$5.38
-0.08 (-1.47 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.37
Now: $5.38
$5.55
50-Day Range
$4.42
MA: $5.11
$5.80
52-Week Range
$2.08
Now: $5.38
$7.10
Volume2.19 million shs
Average Volume5.59 million shs
Market Capitalization$1.24 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.3

Competitors

Endo International (NASDAQ:ENDP) Vs. JNJ, PFE, MRK, ABBV, LLY, and BMY

Should you be buying ENDP stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Endo International, including Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), and Bristol-Myers Squibb (BMY).

Johnson & Johnson (NYSE:JNJ) and Endo International (NASDAQ:ENDP) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Profitability

This table compares Johnson & Johnson and Endo International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Johnson & Johnson21.01%34.64%13.40%
Endo International-5.30%-85.80%7.19%

Earnings & Valuation

This table compares Johnson & Johnson and Endo International's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$82.06 billion4.82$15.12 billion$8.6817.31
Endo International$2.91 billion0.43$-422,640,000.00$2.382.26

Johnson & Johnson has higher revenue and earnings than Endo International. Endo International is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

61.3% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 77.8% of Endo International shares are owned by institutional investors. 0.3% of Johnson & Johnson shares are owned by company insiders. Comparatively, 1.5% of Endo International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Johnson & Johnson has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Endo International has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Johnson & Johnson and Endo International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Johnson & Johnson031002.77
Endo International21402.29

Johnson & Johnson presently has a consensus price target of $166.0769, suggesting a potential upside of 10.52%. Endo International has a consensus price target of $5.50, suggesting a potential upside of 2.23%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, research analysts clearly believe Johnson & Johnson is more favorable than Endo International.

Summary

Johnson & Johnson beats Endo International on 11 of the 14 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Endo International (NASDAQ:ENDP) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Profitability

This table compares Pfizer and Endo International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer28.80%25.11%9.52%
Endo International-5.30%-85.80%7.19%

Earnings & Valuation

This table compares Pfizer and Endo International's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$51.75 billion4.33$16.27 billion$2.9513.67
Endo International$2.91 billion0.43$-422,640,000.00$2.382.26

Pfizer has higher revenue and earnings than Endo International. Endo International is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

69.1% of Pfizer shares are owned by institutional investors. Comparatively, 77.8% of Endo International shares are owned by institutional investors. 0.1% of Pfizer shares are owned by company insiders. Comparatively, 1.5% of Endo International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Pfizer has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Endo International has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Pfizer and Endo International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer09502.36
Endo International21402.29

Pfizer presently has a consensus price target of $40.1429, suggesting a potential downside of 0.49%. Endo International has a consensus price target of $5.50, suggesting a potential upside of 2.23%. Given Endo International's higher probable upside, analysts clearly believe Endo International is more favorable than Pfizer.

Summary

Pfizer beats Endo International on 10 of the 14 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Endo International (NASDAQ:ENDP) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Risk & Volatility

Merck & Co., Inc. has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Endo International has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.

Insider & Institutional Ownership

66.4% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 77.8% of Endo International shares are owned by institutional investors. 0.3% of Merck & Co., Inc. shares are owned by company insiders. Comparatively, 1.5% of Endo International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Merck & Co., Inc. and Endo International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.24.33%53.83%16.83%
Endo International-5.30%-85.80%7.19%

Earnings & Valuation

This table compares Merck & Co., Inc. and Endo International's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$46.84 billion4.43$9.84 billion$5.1915.79
Endo International$2.91 billion0.43$-422,640,000.00$2.382.26

Merck & Co., Inc. has higher revenue and earnings than Endo International. Endo International is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Merck & Co., Inc. and Endo International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.021302.87
Endo International21402.29

Merck & Co., Inc. presently has a consensus price target of $95.3333, suggesting a potential upside of 16.35%. Endo International has a consensus price target of $5.50, suggesting a potential upside of 2.23%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, research analysts clearly believe Merck & Co., Inc. is more favorable than Endo International.

Summary

Merck & Co., Inc. beats Endo International on 11 of the 14 factors compared between the two stocks.

Endo International (NASDAQ:ENDP) and AbbVie (NYSE:ABBV) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.

Risk and Volatility

Endo International has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.

Insider & Institutional Ownership

77.8% of Endo International shares are owned by institutional investors. Comparatively, 64.2% of AbbVie shares are owned by institutional investors. 1.5% of Endo International shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Endo International and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Endo International-5.30%-85.80%7.19%
AbbVie18.16%439.24%13.22%

Earnings and Valuation

This table compares Endo International and AbbVie's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Endo International$2.91 billion0.43$-422,640,000.00$2.382.26
AbbVie$33.27 billion5.69$7.88 billion$8.9412.00

AbbVie has higher revenue and earnings than Endo International. Endo International is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Endo International and AbbVie, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Endo International21402.29
AbbVie141602.71

Endo International presently has a consensus price target of $5.50, suggesting a potential upside of 2.23%. AbbVie has a consensus price target of $111.6667, suggesting a potential upside of 4.09%. Given AbbVie's stronger consensus rating and higher probable upside, analysts plainly believe AbbVie is more favorable than Endo International.

Summary

AbbVie beats Endo International on 11 of the 14 factors compared between the two stocks.

Endo International (NASDAQ:ENDP) and Eli Lilly and (NYSE:LLY) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.

Risk and Volatility

Endo International has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500.

Insider & Institutional Ownership

77.8% of Endo International shares are owned by institutional investors. Comparatively, 69.9% of Eli Lilly and shares are owned by institutional investors. 1.5% of Endo International shares are owned by insiders. Comparatively, 0.1% of Eli Lilly and shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Endo International and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Endo International-5.30%-85.80%7.19%
Eli Lilly and24.01%166.45%15.18%

Earnings and Valuation

This table compares Endo International and Eli Lilly and's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Endo International$2.91 billion0.43$-422,640,000.00$2.382.26
Eli Lilly and$22.32 billion6.36$8.32 billion$6.0424.58

Eli Lilly and has higher revenue and earnings than Endo International. Endo International is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Endo International and Eli Lilly and, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Endo International21402.29
Eli Lilly and05912.73

Endo International presently has a consensus price target of $5.50, suggesting a potential upside of 2.23%. Eli Lilly and has a consensus price target of $168.9286, suggesting a potential upside of 13.79%. Given Eli Lilly and's stronger consensus rating and higher probable upside, analysts plainly believe Eli Lilly and is more favorable than Endo International.

Summary

Eli Lilly and beats Endo International on 12 of the 15 factors compared between the two stocks.

Endo International (NASDAQ:ENDP) and Bristol-Myers Squibb (NYSE:BMY) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.

Risk and Volatility

Endo International has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.

Insider & Institutional Ownership

77.8% of Endo International shares are owned by institutional investors. Comparatively, 64.8% of Bristol-Myers Squibb shares are owned by institutional investors. 1.5% of Endo International shares are owned by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Endo International and Bristol-Myers Squibb's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Endo International-5.30%-85.80%7.19%
Bristol-Myers Squibb-0.11%27.48%10.77%

Earnings and Valuation

This table compares Endo International and Bristol-Myers Squibb's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Endo International$2.91 billion0.43$-422,640,000.00$2.382.26
Bristol-Myers Squibb$26.15 billion5.39$3.44 billion$4.6913.29

Bristol-Myers Squibb has higher revenue and earnings than Endo International. Endo International is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Endo International and Bristol-Myers Squibb, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Endo International21402.29
Bristol-Myers Squibb041202.75

Endo International presently has a consensus price target of $5.50, suggesting a potential upside of 2.23%. Bristol-Myers Squibb has a consensus price target of $74.5294, suggesting a potential upside of 19.61%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, analysts plainly believe Bristol-Myers Squibb is more favorable than Endo International.

Summary

Bristol-Myers Squibb beats Endo International on 10 of the 14 factors compared between the two stocks.


Endo International Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.4$150.27-0.8%$395.59 billion$82.06 billion23.63Increase in Short Interest
Pfizer logo
PFE
Pfizer
2.4$40.34-0.6%$224.23 billion$51.75 billion16.01Analyst Report
Increase in Short Interest
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.4$81.94-0.6%$207.31 billion$46.84 billion18.13
AbbVie logo
ABBV
AbbVie
2.7$107.28-2.4%$189.40 billion$33.27 billion22.68Analyst Upgrade
Insider Selling
Increase in Short Interest
Eli Lilly and logo
LLY
Eli Lilly and
2.4$148.45-2.9%$142.00 billion$22.32 billion24.26Increase in Short Interest
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.2$62.31-0.9%$140.99 billion$26.15 billion-566.40
Zoetis logo
ZTS
Zoetis
1.8$157.95-0.6%$75.07 billion$6.26 billion46.87Insider Selling
Royalty Pharma logo
RPRX
Royalty Pharma
1.6$42.97-1.6%$16.68 billionN/A0.00
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$71.72-0.7%$15.83 billion$1.30 billion19.60Increase in Short Interest
Mylan logo
MYL
Mylan
1.8$15.86-0.0%$8.59 billion$11.50 billion29.92High Trading Volume
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$150.71-0.2%$8.40 billion$2.16 billion47.54Insider Selling
Unusual Options Activity
Heavy News Reporting
Perrigo logo
PRGO
Perrigo
2.4$49.87-3.1%$6.81 billion$4.84 billion28.66Increase in Short Interest
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.6$17.40-1.9%$3.12 billion$114.62 million-7.02Unusual Options Activity
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.6$23.55-0.8%$2.74 billion$306.49 million26.46
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.2$60.61-2.3%$2.63 billion$421.03 million-242.44
Zogenix logo
ZGNX
Zogenix
1.7$22.23-0.7%$1.24 billion$3.65 million-2.34Analyst Report
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.6$22.00-1.1%$1.16 billion$392.76 million9.95Increase in Short Interest
Omeros logo
OMER
Omeros
1.4$14.09-1.2%$868.68 million$111.81 million-6.87Analyst Report
Heavy News Reporting
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$4.03-4.7%$407.48 million$111.39 million28.79Increase in Short Interest
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$6.92-1.6%$315.84 million$16.54 million-2.31
Lannett logo
LCI
Lannett
2.0$6.78-1.6%$282.22 million$545.74 million-9.42
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$6.21-4.3%$205.07 million$15.96 million-3.76Analyst Report
High Trading Volume
Decrease in Short Interest
Heavy News Reporting
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
1.1$2.98-0.0%$44.81 million$47.53 million-13.55High Trading Volume
This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.